Biopharma Insights - page 7)

The Infrastructure Layer: 30 Platforms Powering Human-Relevant Drug Development

Infrastructure for large-scale biomedical data — from multi-omics to EHRs — is converging with a growing policy and business case for data-native drug development. In this article: Clinical Data & Real-World …

Continue ›››

Novotech Report: Over 800 Global IPF Trials Since 2020, Led by Asia-Pacific

Novotech CRO has released a global market analysis focused on the clinical trial landscape for Idiopathic Pulmonary Fibrosis (IPF), identifying strategic trends for drug developers targeting this chronic and progressive …

Continue ›››

The Rise of AI Agents in Biotech, Where Are We Now?

There's been a growing buzz around “AI agents” across the tech ecosystem, with promises of autonomy, automation, and accelerated discovery. In biotech and drug development, however, their real-world presence is still early-stage. …

Continue ›››

23 New Startups in AI Drug Development Space Launched 2023–2025

A snapshot of emerging startups applying AI across the drug development pipeline—from molecular design to clinical decision support. AI began entering biomedical research in the 1970s through early initiatives like …

Continue ›››

13 Foundation Models: Startups, Industry Updates and the Nobel Prize

Since our previous overview of foundation models and start-ups in the life science field, a historical event took place on October 9th, 2024: the Nobel Prize in Chemistry was awarded to David Baker, Demis Hassabis, and John …

Continue ›››

Report: Nearly 80% of Life Sciences Leaders Considering Virtual Models for Observational Research

A new industry report from PicnicHealth reveals that nearly 80% of life sciences leaders are open to using virtual models to improve observational research, citing ongoing challenges with data completeness …

Continue ›››

12 Startups in the Digital Twin Healthcare Ecosystem: From Virtual Organs to Optimized Trials

Despite undeniable progress in life sciences over the last few decades, modern healthcare faces challenges on many fronts. Lengthy drug development processes, often spanning 10 to 15 years, suboptimal clinical …

Continue ›››

Next Generation Sequencing: New Tech and Companies to Watch

From the discovery of the double helix to the latest AI-driven innovations. In this article: Roche’s NGS Trajectory — Sequencing History — NGS in Healthcare — Notable Recent NGS Events — …

Continue ›››

AI in Drug Safety: From Concept to Reality, The Industry's Path Forward

Pharmaceutical companies are dealing with an unprecedented volume of safety data with artificial intelligence moving from theoretical applications to practical solutions in pharmacovigilance. With the FDA now receiving over two …

Continue ›››

Combination Therapies May Be the Future of Oncology – How Can We Navigate Development Challenges Today?

The field of oncology is experiencing a proliferation of cancer therapies. In 2024 alone, the U.S. Food and Drug Administration (FDA) issued more than 60 oncology approvals, including 11 for …

Continue ›››

What CROs Cite as Their Top Clinical Trial Challenges and How They Plan to Overcome Them in 2025

In a rapidly evolving clinical research landscape, there is a greater need now more than ever for pharma and biotech companies to outsource trial management activities to contract research organizations …

Continue ›››